Edison Investment Research - Aberdeen New Dawn Investment Trust PLC (ABD) Update: Termination of coverage

Report

Edison Investment Research

Update: Termination of coverage

Edison Investment Research is terminating coverage on Aberdeen New Dawn
(ABD). Please note you should no longer rely on any previous research or
estimates for this company. All forecasts should now be considered redundant.

05/10/2015 1 EN

Underlying

Aberdeen New Dawn Investment Trust PLC

Aberdeen New Dawn Investment Trust is an investment trust. Co. focuses on providing private and institutional investors capital growth through equity investment. Co.'s assets are invested in a diversified portfolio of securities in quoted companies spread across a range of industries and economies in the Asia Pacific region excluding Japan. Investments may also be made through collective investment schemes and in companies traded on stock markets outside the Asia Pacific region. Co.'s portfolio is managed by Aberdeen Asset Management Asia Limited, a wholly-owned subsidiary of Aberdeen Asset Management PLC.

See profile

GB00BBM56V29 London Stock Exchange United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

QuotedData Professional

abrdn New Dawn – A quality captain for troubled Pacific

abrdn New Dawn (ABD) ended 2022 with the peculiar, if compelling, combination of the second-best 12-month performance within its peer group, and the widest discount, at 11.5%. Manager James Thom has highlighted the ongoing complexity of navigating the Asia Pacific region, given the lack of homogeneity in the varying countries’ outlooks. Whilst ABD has underperformed its benchmark over the last 12 months, as select low-quality stocks have rallied, it remains ahead of its peers, with James’s process generating sector-leading consistency in its outperformance over the longer-term. Though headwin...

February 14, 2023 February 14, 2023 1 EN

QuotedData Retail

abrdn New Dawn – A quality captain for troubled Pacific

abrdn New Dawn (ABD) ended 2022 with the second-best 12-month performance within its peer group, and the widest discount, at 11.5%. Manager James Thom has highlighted the ongoing complexity of navigating the Asia Pacific region, given the lack of homogeneity in the varying countries’ outlooks. Whilst ABD has underperformed its benchmark over the last 12 months, which the manager attributes to a rally in select low-quality stocks, it remains ahead of its peers, with James’s process generating sector-leading consistency in its outperformance over the longer-term. The combination of these return...

February 14, 2023 February 14, 2023 1 EN

QuotedData Professional

Economic and Political Monthly Roundup January 2023

A collation of recent insights on markets and economies taken from the comments made by chairs and investment managers of investment companies – have a read and make your own minds up. Please remember that nothing in this note is designed to encourage you to buy or sell any of the companies mentioned.

January 6, 2023 January 6, 2023 1 EN

AGBA - A transformational deal

On 18 April, AGBA announced a surprise deal to acquire 100% of Triller Corp, a global AI-driven social video platform, in an all-stock transaction. Triller is privately-owned but has been independently valued at US$3.2bn. AGBA’s management is using a US$4bn valuation for the combined entity, in which AGBA shareholders will own 20% and Triller shareholders 80%. Triller recorded FY23 revenues of US$45m on 450m user accounts and 2.2m creators but is loss-making. In FY23, AGBA reported revenues of US$54m and 400,000+ clients. The combined group expects synergies from expanding and marketing to Tri...

4h / 48m 4h / 48m 1 EN

Sean Conroy

Sean Conroy

Biodexa Pharmaceuticals - In a period of transition

FY23 was a transitional year for Biodexa, following the restructuring announced in March 2023 into a therapeutic company from a drug delivery specialist, and the implementation of cost-saving initiatives in light of the macroeconomic environment. The pipeline expansion primarily de-risks the business, partially fulfilled with the acquisition of lyn kinase activator tolimidone, for type 1 diabetes (T1D), in late 2023. Management estimates gross cash of £5.97m at end-FY23 to provide a runway into Q424, past the planned Phase IIa trial initiation for tolimidone. The next catalyst will likely be t...

8h / 58m 8h / 58m 1 EN

Toby Thorrington

Toby Thorrington

Norcros - Sale of Johnson Tiles UK agreed

Norcros’s disposal of Johnson Tiles is the latest strategic activity taken by management to better allocate capital to fit with priorities. Last year it closed its UK adhesives operation. Norcros has a compelling investment case, where its new product development initiatives, market positioning and self-help initiatives allow it to take market share in both the UK and South Africa. Its rating is low at 6.0x FY24e P/E, which is attractive, especially when compared to its yield of 5.4% on its well-covered dividend. We retain our estimates and value the shares at 246p, implying c 30% upside.

April 25, 2024 April 25, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Update: Termination of coverage

abrdn New Dawn – A quality captain for troubled Pacific

abrdn New Dawn – A quality captain for troubled Pacific

Economic and Political Monthly Roundup January 2023

AGBA - A transformational deal

Biodexa Pharmaceuticals - In a period of transition

Norcros - Sale of Johnson Tiles UK agreed

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe